Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Topical micronutrients in atopic dermatitis-An evidence-based review.

Maarouf M, Vaughn AR, Shi VY.

Dermatol Ther. 2018 Jul 17:e12659. doi: 10.1111/dth.12659. [Epub ahead of print] Review.

PMID:
30019437
2.

Myths, Truths, and Clinical Relevance of Comedogenicity Product Labeling.

Maarouf M, Saberian C, Shi VY.

JAMA Dermatol. 2018 Jul 11. doi: 10.1001/jamadermatol.2018.1741. [Epub ahead of print] No abstract available.

PMID:
29998304
3.

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.

Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

PMID:
29980595
4.

An Economic Model of Human Cooperation Based on Indirect Reciprocity and Its Implication on Environmental Protection.

Dai J, Zhang Y, Shi V.

Int J Environ Res Public Health. 2018 Jun 21;15(7). pii: E1303. doi: 10.3390/ijerph15071303.

5.

Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.

Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A.

Int J Cardiol. 2018 Aug 1;264:118-123. doi: 10.1016/j.ijcard.2018.03.121.

6.

Bleach for Atopic Dermatitis.

Maarouf M, Shi VY.

Dermatitis. 2018 May/Jun;29(3):120-126. doi: 10.1097/DER.0000000000000358.

PMID:
29762205
7.

Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation.

Zhu TH, Zhu TR, Tran KA, Sivamani RK, Shi VY.

Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16734. [Epub ahead of print] Review.

PMID:
29761483
8.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV.

JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.

9.
10.

Bleach for Atopic Dermatitis: Beyond Antimicrobials.

Maarouf M, Shi VY.

Dermatitis. 2018 Apr 3. doi: 10.1097/DER.0000000000000358. [Epub ahead of print]

PMID:
29620611
11.

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD.

JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.

PMID:
29617523
12.

Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color.

Lee DE, Clark AK, Shi VY.

Dermatology. 2017;233(6):456-461. doi: 10.1159/000486741. Epub 2018 Mar 1.

13.

Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature.

Maarouf M, Alexander C, Shi VY.

Dermatol Online J. 2018 Jan 15;24(1). pii: 13030/qt4xf465w6. Review.

14.

Unique urticarial presentation of minocycline-induced lupus erythematosus.

Clark AK, Shi VY, Sivamani RK.

Dermatol Online J. 2017 Aug 15;23(8). pii: 13030/qt6w86q8v4.

PMID:
29469742
15.

Familial pseudoxanthoma elasticum associated with multiple comedones.

Maarouf M, Sharon VR, Sivamani RK, Prakash N, Bipin TH, Davis T, Shi VY.

Dermatol Online J. 2017 Sep 15;23(9). pii: 13030/qt82j7181p.

PMID:
29469717
16.

Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW.

PLoS Pathog. 2018 Jan 11;14(1):e1006792. doi: 10.1371/journal.ppat.1006792. eCollection 2018 Jan.

17.

Circadian rhythm in atopic dermatitis-Pathophysiology and implications for chronotherapy.

Vaughn AR, Clark AK, Sivamani RK, Shi VY.

Pediatr Dermatol. 2018 Jan;35(1):152-157. doi: 10.1111/pde.13364. Epub 2017 Dec 12. Review.

PMID:
29231268
18.

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.

Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, Kwan R, Shi V, Blazkova J, Refsland EW, Morris DE, Cohen KW, McElrath MJ, Xu R, Egan MA, Eldridge JH, Benko E, Kovacs C, Moir S, Chun TW, Fauci AS.

Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848. doi: 10.1126/scitranslmed.aan8848.

PMID:
29212716
19.

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2018 Mar;20(3):514-522. doi: 10.1002/ejhf.1056. Epub 2017 Nov 30.

PMID:
29193563
20.

Sweat mechanisms and dysfunctions in atopic dermatitis.

Hendricks AJ, Vaughn AR, Clark AK, Yosipovitch G, Shi VY.

J Dermatol Sci. 2018 Feb;89(2):105-111. doi: 10.1016/j.jdermsci.2017.11.005. Epub 2017 Nov 21. Review.

PMID:
29169766
21.

Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.

Senni M, McMurray JJV, Wachter R, McIntyre HF, Anand IS, Duino V, Sarkar A, Shi V, Charney A.

Eur J Heart Fail. 2018 Mar;20(3):491-500. doi: 10.1002/ejhf.1054. Epub 2017 Nov 22.

PMID:
29164797
22.

Cyanosis of the foot.

Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA.

Cutis. 2017 Oct;100(4):206;209;210. No abstract available.

PMID:
29136053
23.

Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.

Maarouf M, Clark AK, Lee DE, Shi VY.

J Dermatolog Treat. 2018 Aug;29(5):441-449. doi: 10.1080/09546634.2017.1395806. Epub 2017 Nov 10.

PMID:
29098911
24.

New and emerging targeted systemic therapies: a new era for atopic dermatitis.

Lee DE, Clark AK, Tran KA, Shi VY.

J Dermatolog Treat. 2018 Jun;29(4):364-374. doi: 10.1080/09546634.2017.1373736. Epub 2017 Sep 19. Review.

PMID:
28853956
25.

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, Yang S, Kochenderfer JN.

Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.

PMID:
28807568
26.

Health-Related Quality of Life Outcomes in PARADIGM-HF.

Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K.

Circ Heart Fail. 2017 Aug;10(8). pii: e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430.

PMID:
28784687
27.

Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science.

Vaughn AR, Clark AK, Sivamani RK, Shi VY.

Am J Clin Dermatol. 2018 Feb;19(1):103-117. doi: 10.1007/s40257-017-0301-1. Review.

PMID:
28707186
28.

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.

JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. Review.

29.

Paternal vs. Maternal Factors in Childhood Atopic Dermatitis.

Vaughn AR, Sivamani RK, Lio PA, Shi VY.

Dermatitis. 2017 Jul/Aug;28(4):241-245. doi: 10.1097/DER.0000000000000305. Review.

PMID:
28614111
30.

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Am Heart J. 2017 Jun;188:35-41. doi: 10.1016/j.ahj.2017.02.034. Epub 2017 Mar 14.

PMID:
28577679
31.

Mother Nature in Eczema: Maternal Factors Influencing Atopic Dermatitis.

Vaughn AR, Tannhauser P, Sivamani RK, Shi VY.

Pediatr Dermatol. 2017 May;34(3):240-246. doi: 10.1111/pde.13149. Review.

PMID:
28523877
32.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003800. doi: 10.1161/CIRCHEARTFAILURE.116.003800.

33.

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD.

Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18.

34.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA.

J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14.

35.

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.

Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV.

Eur Heart J. 2017 Apr 14;38(15):1132-1143. doi: 10.1093/eurheartj/ehw570.

PMID:
28158398
36.

The Endocannabinoid System and Its Role in Eczematous Dermatoses.

Trusler AR, Clark AK, Sivamani RK, Shi VY.

Dermatitis. 2017 Jan/Feb;28(1):22-32. doi: 10.1097/DER.0000000000000257. Review.

PMID:
28098721
37.

Sacubitril/Valsartan (LCZ696) in Heart Failure.

Khder Y, Shi V, McMurray JJV, Lefkowitz MP.

Handb Exp Pharmacol. 2017;243:133-165. doi: 10.1007/164_2016_77. Review.

PMID:
28004291
38.

Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.

Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD.

J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436. doi: 10.1016/j.jacc.2016.09.931.

40.

Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment.

Kartan S, Shi VY, Clark AK, Chan LS.

Am J Clin Dermatol. 2017 Feb;18(1):105-126. doi: 10.1007/s40257-016-0235-z. Review.

PMID:
27878477
41.

Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.

Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2017 Jan;19(1):129-137. doi: 10.1002/ejhf.687. Epub 2016 Nov 20.

42.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD.

JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733.

PMID:
27842179
43.

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.

Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*.

Circ Heart Fail. 2016 Sep;9(9). pii: e003212. doi: 10.1161/CIRCHEARTFAILURE.116.003212.

PMID:
27618854
44.

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.

Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD; PARADIGM-HF Investigators.

J Am Coll Cardiol. 2016 Jul 19;68(3):241-248. doi: 10.1016/j.jacc.2016.04.047.

45.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN.

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

46.

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN.

JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226.

PMID:
27411054
47.

Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.

Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV.

JACC Heart Fail. 2016 Oct;4(10):816-822. doi: 10.1016/j.jchf.2016.05.002. Epub 2016 Jul 6.

48.

Geographic variations in the PARADIGM-HF heart failure trial.

Kristensen SL, Martinez F, Jhund PS, Arango JL, Bĕlohlávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ.

Eur Heart J. 2016 Nov 1;37(41):3167-3174. Epub 2016 Jun 28.

49.

Objective volumetric grading of postacne scarring.

Petukhova TA, Foolad N, Prakash N, Shi VY, Sharon VR, O'Brecht L, Ali IA, Feldstein S, Halls J, Wang Q, Li CS, Sivamani RK.

J Am Acad Dermatol. 2016 Jul;75(1):229-31. doi: 10.1016/j.jaad.2016.03.002. No abstract available.

PMID:
27317527
50.

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.

Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M.

Circ Heart Fail. 2016 Jun;9(6). pii: e002735. doi: 10.1161/CIRCHEARTFAILURE.115.002735.

PMID:
27296397

Supplemental Content

Support Center